OncoMatch/Clinical Trials/NCT06954584
Fluzoparib+Bevacizumab/Dietary Intervention vs Fluzoparib Monotherapy as First-line Maintenance in HRD+/- Advanced Ovarian Cancer
Is NCT06954584 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including Bevacizumab and Fluzoparib Monotherapy for ovarian cancer.
Treatment: Bevacizumab · Fluzoparib Monotherapy — Fluzoparib has been approved for the first-line maintenance treatment of advanced ovarian cancer in the full population . Previous studies have demonstrated that anti-angiogenic agents enhance tumor cell sensitivity to PARP inhibitors . In vitro evidence suggests that low-carbohydrate culture conditions may restore PARP inhibitor sensitivity in HRD-negative tumor cells. This study aims to validate the survival benefits of fluzoparib combined with bevacizumab in HRD-positive ovarian cancer patients during first-line maintenance therapy and explore the efficacy of fluzoparib combined with a dietary intervention in HRD-negative populations.
Check if I qualifyExtracted eligibility criteria
Cancer type
Ovarian Cancer
Disease stage
Required: Stage III, IV
Grade: high-grade; grade ≥ii for endometrioid
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: platinum-based chemotherapy — first-line
Completed platinum-based chemotherapy with the following requirements: * Patients unable to tolerate chemotherapy for definitive reasons must complete at least 4 cycles of platinum-based chemotherapy. * Patients undergoing interval debulking surgery must complete at least 3 cycles of platinum-based chemotherapy post-surgery.
Cannot have received: PARP inhibitor (olaparib, niraparib, rucaparib, pamiparib, fluzoparib)
Prior use of PARP inhibitors (e.g., olaparib, niraparib, rucaparib, pamiparib, fluzoparib)
Lab requirements
Blood counts
ANC ≥1.5×10⁹/L; Platelets ≥90×10⁹/L; Hemoglobin ≥9 g/dL; Serum albumin ≥3 g/dL
Kidney function
Serum creatinine ≤1.5×ULN
Liver function
Total bilirubin ≤1.5×ULN; ALT and AST ≤2.5×ULN
Adequate organ function (no blood transfusions or growth factors within 14 days prior to randomization): -Absolute neutrophil count (ANC) ≥1.5×10⁹/L. -Platelets ≥90×10⁹/L. -Hemoglobin ≥9 g/dL. -Serum albumin ≥3 g/dL. -Total bilirubin ≤1.5×ULN. -ALT and AST ≤2.5×ULN. * Serum creatinine ≤1.5×ULN.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify